Pulse Biosciences (NASDAQ:PLSE) Upgraded to “Buy” at ValuEngine

Pulse Biosciences (NASDAQ:PLSE) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, ValuEngine reports.

PLSE has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating on shares of Pulse Biosciences in a report on Wednesday, May 1st. BidaskClub lowered Pulse Biosciences from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 16th.

Pulse Biosciences stock traded down $0.13 during mid-day trading on Thursday, reaching $12.51. 63,693 shares of the company were exchanged, compared to its average volume of 33,460. The firm’s fifty day moving average is $12.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.13 and a current ratio of 17.13. The firm has a market cap of $270.48 million, a price-to-earnings ratio of -5.69 and a beta of 1.79. Pulse Biosciences has a 12-month low of $8.60 and a 12-month high of $19.77.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Tuesday, April 30th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). As a group, equities research analysts predict that Pulse Biosciences will post -2.09 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of PLSE. Steward Partners Investment Advisory LLC bought a new position in shares of Pulse Biosciences in the second quarter worth $55,000. Westside Investment Management Inc. bought a new position in shares of Pulse Biosciences in the second quarter worth $5,074,000. Griffin Asset Management Inc. bought a new position in shares of Pulse Biosciences in the first quarter worth $903,000. BNP Paribas Arbitrage SA increased its position in shares of Pulse Biosciences by 1,082.7% in the first quarter. BNP Paribas Arbitrage SA now owns 2,259 shares of the company’s stock worth $40,000 after purchasing an additional 2,068 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Pulse Biosciences by 49.5% in the fourth quarter. Geode Capital Management LLC now owns 117,149 shares of the company’s stock worth $1,342,000 after purchasing an additional 38,763 shares during the period. Institutional investors own 9.19% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

Featured Article: Percentage Decliners

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.